OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

A new UK biotech, OMass Therapeutics, has been spun out of the chemistry department at the University of Oxford to exploit expertise in "native" mass spectrometry, a technology investors believe has potential in helping to build a portfolio of novel drugs. That ambition was supported last month by the raising of £14m in series A funding from investors.

Dame Carol Robinson, a professor at the university and an OMass founder and advisor, and her colleagues, have been pioneers in the application of high-resolution native mass spectrometry to membrane proteins, but more recently